Workflow
贝达药业递表港交所 联席保荐人为摩根士丹利和中信证券
Zheng Quan Shi Bao Wang·2025-09-30 00:48

Group 1 - The core viewpoint of the article is that BeiGene has submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and CITIC Securities as joint sponsors [1] - The company has successfully transformed into a "platform-based pharmaceutical enterprise," integrating commercialization capabilities, drug research and development, business development layout, and an innovative ecosystem [1] - BeiGene is a pioneer and leader in China's innovative drug research and development industry, focusing on new drugs for cancer treatment, particularly leading in lung cancer therapy [1] Group 2 - The company has established a drug pipeline covering key lung cancer targets such as EGFR and ALK through independent research and strategic partnerships, and has expanded into breast cancer, kidney cancer, hematology, and ophthalmology [1] - To date, the company has successfully launched eight commercialized products, including five innovative drugs, one biosimilar, and two co-marketing products [1]